Overview

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Status:
Unknown status
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
A clinical trial is being conducted to test the effects of a potential new treatment in patients with ulcerative colitis. Study participants will be given capsules containing either ORE1001 or a matching placebo capsule and will take the medicine by mouth for six weeks. Study participants will be asked to visit clinic sites where they will be asked questions about their ulcerative colitis. Small samples of blood will be be drawn at study visits to monitor the participant's health and a tiny sample of tissue will be taken in an endoscopy at two times to determine whether the disease is getting better or worse.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ore Pharmaceuticals, Inc.